INTRODUCTION {#S1}
============

The organization of actin filaments into bundles and networks is essential for the diverse cellular functions of the actin cytoskeleton. Fascin is a pro-metastasis actin-bundling protein required for the maximal crosslinking of F-actin into straight and rigid bundles ([@R45]). Fascin overexpression invariably correlates with aggressive clinical course, metastatic progression, and shorter survival across different types of carcinoma ([@R12]; [@R31]). It is generally believed that fascin plays a mechanical role in driving tumor cell migration and invasion by facilitating membrane protrusions. However, there is also evidence implicating fascin in oncogenesis ([@R37]), metastatic colonization([@R22]), anoikis resistance, chemoresistance, and cancer cell stemness ([@R2]). Molecular mechanisms underlying these non-canonical functions of fascin are not clear.

Mitochondria are highly dynamic powerhouses of the cell constantly undergoing fission and fusion ([@R10]). The division of mitochondria is initiated by constriction of the mitochondrial fission site by the endoplasmic reticulum (ER) tubule and followed by membrane scission mediated by the dynamin-related protein 1 (Drp1) ([@R11]; [@R16]; [@R18]; [@R29]). The ER-anchored inverted formin 2-CAAX (INF2-CAAX) facilitates the polymerization of F-actin at the ER-mitochondrion contacts, which provides mechanical forces for the initial mitochondrial constriction ([@R16]; [@R18]). Cortactin, Arp2/3 complex, myosin II, and several other actin regulatory proteins are also implicated in the assembly and regulation of mitochondrial F-actin ([@R9]; [@R23]; [@R29]). It is unclear whether or how the actin cytoskeleton dysregulation during metastatic progression might affect mitochondrial actin filaments (mtF-actin) or mitochondrial metabolism.

Here, we report a role of fascin in the control of metastatic colonization and mitochondrial oxidative phosphorylation (OXPHOS) by remodeling mtF-actin. Our findings implicate that the dysregulation of the actin cytoskeleton in post-dissemination cells is able to control lung cancer metastasis by rewiring mitochondrial metabolism. Small molecule inhibitors targeting fascin could be potentially used to prevent metastatic recurrence by reprogramming mitochondrial metabolism.

RESULTS {#S2}
=======

Fascin Is Required for Metastatic Colonization and Metabolic Stress Resistance {#S3}
------------------------------------------------------------------------------

Our immunohistochemistry analysis of lung cancer patient specimens supported that fascin expression was highly elevated in lung adenocarcinoma patients ([Figures 1A](#F1){ref-type="fig"} and [1B](#F1){ref-type="fig"}). Fascin overexpression was associated with larger tumor size, lymph node involvement, advanced staging, and shorter survival ([Figure 1C](#F1){ref-type="fig"}; [Table S1](#SD1){ref-type="supplementary-material"}). To understand the role of fascin in lung cancer metastasis, we used short hairpin RNA (shRNA) or CRISPR/Cas9 to deplete the expression of fascin in lung adenocarcinoma cells ([Figure S1A](#SD1){ref-type="supplementary-material"}). Depletion of fascin blocked the tumor metastasis of tail-vein-injected H292 cells, implicating a causal role of fascin in metastatic colonization ([Figures 1D](#F1){ref-type="fig"} and [1E](#F1){ref-type="fig"}).

Next, we investigated whether fascin has a post-dissemination role in lung cancer metastasis. Because the extravasation of cancer cells from the microvasculature is dependent on cell mobility and invasiveness, we used inducible CRISPR/Cas9 to interrogate the post-extravasation function of fascin in metastatic expansion. In this system, doxycycline induced the expression of Cas9 and the depletion of fascin protein in about 7 days ([Figure S1B](#SD1){ref-type="supplementary-material"}). Luciferase-labeled Lewis lung cancer (LLC) cells stably expressing Tet-On Cas9 and fascin single-guide RNA (sgRNA) were injected into albino BL6 mice by tail vein. Forty-eight hours after tail-vein injection, the mice were fed with doxycycline chow to induce the expression of Cas9 and the deletion of fascin ([Figure 1F](#F1){ref-type="fig"}). At 48-h post-tail-vein injection, more than 95% of LLC cells had already extravasated to the lung parenchyma ([Figures S1C](#SD1){ref-type="supplementary-material"} and [S1D](#SD1){ref-type="supplementary-material"}). Depletion of fascin in post-extravasation LLC cells dramatically inhibited the development of LLC lung metastases ([Figures 1G](#F1){ref-type="fig"} and [1H](#F1){ref-type="fig"}; [Figure S1E](#SD1){ref-type="supplementary-material"}). Only micrometastases were detected in the lung after inducible depletion of fascin in post-dissemination LLC cells ([Figure S1F](#SD1){ref-type="supplementary-material"}). In contrast, fascin knockout (KO) was only able to marginally inhibit the tumor growth of subcutaneous LLC xenograft ([Figure S1G](#SD1){ref-type="supplementary-material"}; n = 10, p = 0.08), suggesting that fascin is more critical for metastatic expansion than for primary tumor growth. Immunohistochemistry (IHC) analysis indicated that residual micro-metastases in the lung were positive for fascin expression, indicating these residual micro-lesions might be due to incomplete depletion of fascin ([Figure S1H](#SD1){ref-type="supplementary-material"}). Pharmacological inhibition of fascin using the small molecule inhibitor G2 ([@R14] in post-extravasation LLC cells was also able to markedly inhibit metastatic expansion ([Figures 1I](#F1){ref-type="fig"} and [1J](#F1){ref-type="fig"}). Taken together, our data suggest fascin is required for the metastatic expansion of disseminated lung cancer cells, which could be potentially targeted to prevent metastatic recurrence.

Overcoming metabolic stress is crucial for disseminated cancer cells to establish distant metastases. The glucose concentration in the tumor microenvironment is as much as 10 times lower than in the normal tissue ([@R4]; [@R26]. Glucose uptake is also dramatically inhibited when cancer cells lose adhesion to the extracellular matrix (e.g., circulating tumor cells), which results in oxidative stress and anoikis ([@R36]). Therefore, we examine the effects of fascin KO and knockdown on non-small cell lung cancer (NSCLC) cell proliferation under regular cell culture conditions (10 mM glucose \[Glc\]) and glucose-limited conditions (1 mM glucose). Fascin depletion with CRISPR/Cas9 or shRNA had no effect on lung cancer cell proliferation under a physiological concentration of glucose (10 mM) ([Figure 1K](#F1){ref-type="fig"}; [Figures S1I](#SD1){ref-type="supplementary-material"} and [S1J](#SD1){ref-type="supplementary-material"}). However, when the glucose availability was limited (1 mM glucose), the proliferation of fascin-depleted cells was significantly slower ([Figures 1K](#F1){ref-type="fig"}, [S1I](#SD1){ref-type="supplementary-material"}, and [S1J](#SD1){ref-type="supplementary-material"}). Fascin depletion also remarkably inhibited soft agar colony formation and resistance to cell death induced by biguanide metabolic drug phenformin ([Figures 1L](#F1){ref-type="fig"}--[1N](#F1){ref-type="fig"}). Conversely, fascin overexpression in NSCLC cells remarkably promoted cell proliferation and survival under metabolic stresses (glucose limitation, loss-of-adhesion, and phenformin treatment) ([Figures 1K](#F1){ref-type="fig"}, [1L](#F1){ref-type="fig"}, and [1N](#F1){ref-type="fig"}; [Figures S1I](#SD1){ref-type="supplementary-material"}--[S1J](#SD1){ref-type="supplementary-material"}), suggesting that fascin overexpression in NSCLC promotes metabolic stress resistance to facilitate metastatic colonization.

Fascin Overexpression Promotes Mitochondrial OXPHOS in Lung Cancer Cells {#S4}
------------------------------------------------------------------------

In order to understand the mechanism by which fascin controls metabolic stress resistance, we analyzed the levels of approximately 280 polar metabolites in control and fascin KO H1650 cells by using liquid chromatography-tandem mass spectrometry (LC-MS/MS). The metabolome of the fascin KO group clustered distinctly from that of control cells ([Figure S2A](#SD1){ref-type="supplementary-material"}). The most significantly altered metabolic pathways in fascin KO cells included nicotinamide metabolism, glutathione, and methionine metabolic pathways ([Figure 2A](#F2){ref-type="fig"}; [Figures S2B](#SD1){ref-type="supplementary-material"} and [S2C](#SD1){ref-type="supplementary-material"}). The TCA (tricarboxylic acid) cycle was also among the altered metabolic pathways in fascin-depleted lung cancer cells ([Figure 2A](#F2){ref-type="fig"}). We confirmed that fascin KO decreased NAD+ and NADH levels ([Figure 2B](#F2){ref-type="fig"}), suggesting a critical role for fascin in NSCLC nicotinamide homeostasis.

Mitochondrial respiration is crucial for nicotinamide metabolism ([@R4]; [@R41]) and metabolic stress resistance ([@R4]; [@R26]; [@R41]). To determine whether fascin might control mitochondrial metabolism, we performed stable isotope tracing analysis by incubating control or fascin KO H1650 cells with \[U-^13^C\]-glucose. The incorporation of ^13^C to a targeted panel of TCA cycle metabolites in the cell was then analyzed using LC-MS. As shown in [Figures 2C](#F2){ref-type="fig"} and [2D](#F2){ref-type="fig"}, there was about a 30%--50% decrease in the levels of M+2 α-ketoglutarate aconitate, citrate and isocitrate, fumarate, malate, and glutamate; in contrast, the levels of M+2 acetyl-coenzyme A (CoA) increased by about 2-fold, suggesting inhibition of metabolic flux to the TCA cycle in fascin-depleted cells. To further determine the role of fascin in mitochondrial metabolism, we used a mito-stress test to evaluate the effects of fascin depletion or overexpression on mitochondrial oxygen consumption rate in lung cancer cells. As shown in [Figures 2E](#F2){ref-type="fig"} and [2F](#F2){ref-type="fig"}; [Figures S2D](#SD1){ref-type="supplementary-material"} and [S2E](#SD1){ref-type="supplementary-material"}, fascin depletion with CRISPR/Cas9 or shRNA dramatically inhibited basal, ATP-linked, and maximal oxygen consumption rates (OCRs) in all the tested NSCLC cells. Conversely, fascin overexpression in NSCLC cells remarkably increased mitochondrial OCR, strongly supporting an essential role for fascin in mitochondrial OXPHOS ([Figures 2G](#F2){ref-type="fig"} and [2E](#F2){ref-type="fig"} ; [Figure S2F](#SD1){ref-type="supplementary-material"}). To determine whether the ability to promote mitochondrial respiration is specific to fascin, we overexpressed fimbrin, another actin-bundling protein with similar actin crosslinking properties to fascin, in H1650 cells. The overexpression of fimbrin had no effects on mitochondrial OXPHOS ([Figures S2G](#SD1){ref-type="supplementary-material"} and [S2H](#SD1){ref-type="supplementary-material"}). Taken together, our data support that fascin overexpression in lung cancer is able to enhance mitochondrial OXPHOS.

Fascin Controls OXPHOS by Remodeling mtF-Actin {#S5}
----------------------------------------------

To understand the mechanism by which fascin controls OXPHOS, we first asked whether fascin regulates mitochondrial metabolism through its actin-bundling activity. According to the crystal structure and mutagenesis studies of fascin ([@R6]; [@R38]), there are two major actin-binding sites in the fascin structure ([@R24]; [@R54]). Two of the fascin mutants (S39E at site 1 and R149A/K150A/R151A, or 149-151A for short, at site 2) have lost bundling activity without changing the global protein structure ([@R54]). When expressed in fascin knockdown H1650 cells, wild-type fascin was able to rescue mitochondrial OCRs and NAD+ and NADH levels ([Figures 3A](#F3){ref-type="fig"}--[3D](#F3){ref-type="fig"}; [Figure S3A](#SD1){ref-type="supplementary-material"}). Mutations at the two separate actin-binding sites completely abrogated the ability of fascin to restore mitochondrial OCRs and nicotinamide levels ([Figures 3A](#F3){ref-type="fig"}--[3D](#F3){ref-type="fig"}), suggesting that fascin regulates mitochondrial metabolism through actin crosslinking.

The mtF-actin has recently been implicated in mitochondrial dynamics ([@R9]; [@R16]; [@R18], [@R19]; [@R23]; [@R29]), although the role of mtF-actin in cancer metabolism is unknown. Because fascin-mediated control of mitochondrial metabolism depends on its actin-bundling activity, we evaluated the effects of fascin depletion on mtF-actin accumulation in NSCLC cells. Mitochondria in NSCLC cells have very diverse morphologies, ranging from bead-like, fragmented structures (in LLC cells) and inter-connected networks spreading throughout the cell (H1650 cells) to thread-like structures mostly concentrated on one side of the nucleus (in H23 cells) (data not shown). When F-actin was stained with phalloidin, we observed constitutive mtF-actin accumulated at bead-like mitochondria in the majority of LLC cells (\>80%) under regular cell culture conditions ([Figures 2E](#F2){ref-type="fig"} and [2F](#F2){ref-type="fig"}). Fascin depletion in LLC cells resulted in elongated mitochondria and reduced the proportion of mtF-actin-positive cells to approximately 20% ([Figures 2E](#F2){ref-type="fig"} and [2F](#F2){ref-type="fig"}). No mtF-actin was observed in H23 under conventional cell culture conditions ([Figure S3B](#SD1){ref-type="supplementary-material"}). However, treatment of H23 cells with glucose limitation (1 mM glucose) or trifluoromethoxy carbonylcyanide phenylhydrazone (FCCP) induced mitochondrial fragmentation and accumulation of mtF-actin in 50%--100% of cells, which was abrogated by the depletion of fascin ([Figure 3G](#F3){ref-type="fig"}; [Figures S3B](#SD1){ref-type="supplementary-material"} and [S3C](#SD1){ref-type="supplementary-material"}). We were not able to evaluate mtF-actin in H1650 and H292 cells due to strong background staining of F-actin in these cells (data not shown). Taken together, our data implicate a crucial role for fascin in metabolic-stress-induced mtF-actin accumulation.

To determine whether fascin might be directly recruited to regulate mtF-actin under metabolic stress, we examined the effects of metabolic stress on the localization of fascin in lung cancer cells. No localization of EGFP-fascin was observed in H23 cells cultured in medium containing 10 mM glucose ([Figure S3D](#SD1){ref-type="supplementary-material"}). However, glucose limitation (1mM glucose) induced robust recruitment of fascin to fragmented mitochondria in H23 cells ([Figures 3H](#F3){ref-type="fig"} and [3I](#F3){ref-type="fig"}). Interestingly, shRNA depletion of INF2-CAAX (an ER-anchored splicing variant of INF2 that is responsible for ER-originated mtF-actin assembly) was able to abrogate the recruitment of fascin to mitochondria under glucose limitation ([Figures 3H](#F3){ref-type="fig"} and [3I](#F3){ref-type="fig"}; [Figure S3E](#SD1){ref-type="supplementary-material"}). Mitochondrial stress induced by FCCP was also able to induce strong mitochondrial recruitment of fascin in lung cancer cells, which was abrogated by the knock down of INF2-CAAX ([Figure 3I](#F3){ref-type="fig"}; [Figures S3E](#SD1){ref-type="supplementary-material"}--[S3H](#SD1){ref-type="supplementary-material"}). Interestingly, although cortactin and the Arp2/3 complex have also been reported to regulate mtF-actin, knock down of cortactin or inhibition of the Arp2/3 complex with inhibitor had no effect on stress-induced recruitment of fascin to mitochondria ([Figures S3I](#SD1){ref-type="supplementary-material"} and [S3J](#SD1){ref-type="supplementary-material"})

Next, we wished to investigate whether fascin controls mitochondrial OXPHOS through remodeling mtF-actin. The knock down of INF2-CAAX remarkably inhibited mitochondrial OCRs and decreased the levels of NAD+ and NADH in NSCLC cells ([Figures S4A](#SD1){ref-type="supplementary-material"}--[S4C](#SD1){ref-type="supplementary-material"}). However, the shRNA depletion of cortactin or inhibition of the Arp2/3 complex with CK666 has no effect on mitochondrial OXPHOS ([Figure S4D](#SD1){ref-type="supplementary-material"}), suggesting that only ER-originated mtF-actin is required for mitochondrial metabolism. To determine whether INF2-mediated mtF-actin is required for fascin to promote mitochondrial OXPHOS, we knocked down INF2-CAAX in control or fascin-overexpressing NSCLC cells. The knock down of INF2-CAAX in NSCLC cells was able to abrogate the augmentation of mitochondrial OXPHOS in fascin-overexpressing cells, suggesting that ER-originated mtF-actin is required for fascin to promote mitochondrial OXPHOS ([Figures 3J](#F3){ref-type="fig"} and [3K](#F3){ref-type="fig"}; [Figure S4E](#SD1){ref-type="supplementary-material"})

Fascin Regulates the Biogenesis of Respiration Complexes through mtF-Actin {#S6}
--------------------------------------------------------------------------

To understand the molecular mechanisms by which fascin regulates mitochondrial OXPHOS, we used tandem mass tag (TMT) and chemical labeling and LC-MS/MS to evaluate the proteomic changes in fascin KO H1650 cells. Over 6,000 proteins were detected and quantified by LC-MS/MS. The expression levels of 76 proteins were differentially expressed (log~2~ ratio changes exceeding 2σ away from the mean) in fascin KO cells. Twelve differentially regulated targets are mitochondrial proteins ([Figure 4A](#F4){ref-type="fig"}; [Table S2](#SD1){ref-type="supplementary-material"}), notably including two subunits of the mitochondrial Complex I (NDUFA4 and NDUFB8) ([Figure 4A](#F4){ref-type="fig"}). Indeed, we confirmed that the protein levels of Complex I subunits NDUFB8, NDUFA4, and mt-ND1 are significantly reduced in fascin KO NSCLC cells ([Figures 4B](#F4){ref-type="fig"} and [4C](#F4){ref-type="fig"}). Conversely, ectopic expression of wild-type fascin, but not the two bundling defective mutants, was able to increase the levels of mt-ND1 ([Figures 4D](#F4){ref-type="fig"} and [4E](#F4){ref-type="fig"}). The overexpression of fimbrin had no effect on the expression of mt-ND1 and NDUFB8 ([Figure S5A](#SD1){ref-type="supplementary-material"}). Disruption of mtF-actin with INF2-CAAX shRNA similarly decreased the protein levels of Complex I subunits ([Figure S5B](#SD1){ref-type="supplementary-material"}). In contrast, cortactin knock down or Arp2/3 inhibitor treatment had no effect on the Complex I protein level ([Figures S5C](#SD1){ref-type="supplementary-material"} and [S5D](#SD1){ref-type="supplementary-material"}). Importantly, the depletion of INF2-CAAX was able to abrogate the fascin-mediated increase in Complex I protein levels ([Figures 4F](#F4){ref-type="fig"} and [S5E](#SD1){ref-type="supplementary-material"}), suggesting that ER-originated mtF-actin is required for fascin to promote Complex I biogenesis.

It is believed that complexes I, III, and IV are able to assemble into supercomplexes to facilitate electron transfer ([@R20]). To investigate the regulation of respiratory chain biogenesis by fascin, we determined the levels of respiratory supercomplexes in fascin KO cells. As shown in [Figure 4H](#F4){ref-type="fig"}, Complex I in H1650 cells was almost exclusively present in respirasomes in NSCLC cells (supercomplexes consisting of I, III, and IV). Fascin depletion decreased the levels of respirasomes by about 80% ([Figure 4G](#F4){ref-type="fig"}). Also decreased are supercomplexes III~2~+IV~1~, III~2~, and V~n~, while there was little change in the Complex IV monomer ([Figure 4G](#F4){ref-type="fig"}). Interestingly, shRNA knock down of INF2-CAAX similarly reduced the levels of respirasomes and other supercomplexes ([Figure 4H](#F4){ref-type="fig"}), indicating that disruption of mtF-actin is able to recapitulate the effects of fascin depletion. Taken together, our data indicate that fascin controls the biogenesis of respiratory chain by remodeling mtF-actin.

To evaluate the possibility that fascin may regulate respiratory complex biogenesis in lung cancer patients, we used IHC to determine the expression of NDUFB8 in our lung adenocarcinoma tissue microarray ([Figure 5A](#F5){ref-type="fig"}). The overexpression of NDUFB8 in lung adenocarcinoma strongly correlated with poor overall survival (HR = 2.44, p = 0.001), larger tumor size, lymph node metastasis, and advanced TNM (tumor size, lymph node involvement, and distant metastasis) staging ([Figure 5B](#F5){ref-type="fig"}; [Table S3](#SD1){ref-type="supplementary-material"}), indicating a crucial role for mitochondrial respiration in NSCLC progression. Importantly, lung adenocarcinoma specimens with strong fascin staining also have high NDUFB8 expression ([Figures 5C](#F5){ref-type="fig"} and [5D](#F5){ref-type="fig"}) (rs = 0.434, p = 0.0025), supporting a role for fascin in the biogenesis of Complex I in lung cancer patients. Taken together, our data supported that fascin promotes the biogenesis of mitochondrial respiratory complexes in NSCLC to augment mitochondrial OXPHOS.

Fascin and mtF-Actin Are Required for the Homeostasis of mtDNA in NSCLC {#S7}
-----------------------------------------------------------------------

To investigate the mechanism by which fascin and mtF-actin modulate respiratory chain biogenesis, we determined the protein stability and mRNA transcript levels of nuclear-DNA- and mtDNA-encoded respiratory complex subunits ([Figures 6A](#F6){ref-type="fig"}--[6C](#F6){ref-type="fig"}). Fascin depletion decreased the stability of nuclear-encoded NDUFB8 ([Figure 6A](#F6){ref-type="fig"}) and the mtDNA-encoded mt-ND1 ([Figure 6B](#F6){ref-type="fig"}). Intriguingly, although the RNA transcript levels of mtDNA-encoded genes were significantly decreased after fascin depletion, there was no change in the mRNA levels of nuclear-DNA-encoded Complex I subunits ([Figure 6C](#F6){ref-type="fig"}). The levels of mtDNA and mtDNA-encoded transcript levels were also remarkably decreased after fascin or INF2-CAAX depletion ([Figures S6A](#SD1){ref-type="supplementary-material"}--[S6C](#SD1){ref-type="supplementary-material"}), indicating that fascin and mtF-actin controls biogenesis of respiratory complexes through mtDNA homeostasis. We further investigated the effects of fascin overexpression on mtDNA levels. The overexpression of fascin increased mtDNA levels by approximately 30% in lung cancer cells, which was abrogated by the knock down of INF2-CAAX ([Figure S6D](#SD1){ref-type="supplementary-material"}), suggesting that fascin controls mtDNA homeostasis through mtF-actin remodeling.

The ER networks are important sensors to cellular stresses, such as unfolded protein response and oxidative stress ([@R47]; [@R48]). In addition, the ER-mitochondrial contact in the proximity of nucleoids is required for mtDNA replication and for the proper segregation of newly replicated mtDNA nucleoids to daughter mitochondria ([@R10]; [@R21]; [@R30]). Because our data support that INF2-CAAX-mediated, ER-originated mtF-actin is required for fascin to promote mitochondrial OXPHOS, we examined the effects of fascin depletion on mtDNA nucleoids by using immunofluorescence staining. mtDNA nucleoids are evenly distributed in the mitochondrial network of control NSCLC cells ([Figures 6D](#F6){ref-type="fig"} and [S6E](#SD1){ref-type="supplementary-material"}). The depletion of fascin led to striking changes in mtDNA nucleoid morphology and distribution ([Figures 6D](#F6){ref-type="fig"} and [S6E](#SD1){ref-type="supplementary-material"}). There were long stretches of nucleoid-free mitochondria, aggregation, and enlargement of multiple mtDNA nucleoids in fascin KO H1650 and H23 cells ([Figures 6D](#F6){ref-type="fig"} and [S6E](#SD1){ref-type="supplementary-material"}). Treatment with DNase I completely abolished the staining of these aggregates, confirming the staining specificity for mtDNA ([Figure S6F](#SD1){ref-type="supplementary-material"}). Notably, many of the nucleoid aggregates in fascin KO H1650 cells appeared to be on the cytosolic side of the mitochondrial membrane ([Figure 6D](#F6){ref-type="fig"}, arrow), implicating leakage of mtDNA to the cytosol. When quantified by qPCR, the levels of cytosolic mtDNA were two to three times higher in fascin KO cells ([Figures 6E](#F6){ref-type="fig"} and [S6G](#SD1){ref-type="supplementary-material"}), further supporting the notion of mtDNA leakage after fascin depletion.

To determine the role of fascin-bundling activities in its control of mtDNA homeostasis, we ectopically expressed wild-type fascin or bundling-defective mutants (S39E and 149-151A) in fascin knockdown cells ([Figure 6F](#F6){ref-type="fig"}). Fascin knockdown with shRNA similarly induced mtDNA aggregation in approximately 80% of cells ([Figures 6F](#F6){ref-type="fig"} and [S6H](#SD1){ref-type="supplementary-material"}). The ectopic expression of wild-type fascin in fascin knockdown cells remarkably prevent mtDNA aggregation ([Figures 6F](#F6){ref-type="fig"} and [S6H](#SD1){ref-type="supplementary-material"}) and cytosolic mtDNA leakage ([Figure 6G](#F6){ref-type="fig"}). As a consequence, wild-type fascin was also able to restore the levels of mtDNA copies and mtDNA-encoded transcripts in fascin knockdown cells ([Figures 6H](#F6){ref-type="fig"} and [6I](#F6){ref-type="fig"}). In contrast, the ectopic expression of the two bundling-defective mutants had no rescue effects on mtDNA aggregation and leakage and was not able to restore the levels of mtDNA copies and mtDNA-encoded transcripts ([Figures 6F](#F6){ref-type="fig"}--[6I](#F6){ref-type="fig"} and [S6H](#SD1){ref-type="supplementary-material"}). Taken together, our data support that fascin controls mtDNA homeostasis through mtF-actin remodeling

The INF2-CAAX and mtF-actin have recently been implicated in the recruitment and activation of Drp1 fission complexes ([@R13]; [@R16]). Therefore, we investigated the role of Drp1 in fascin-mediated mitochondrial OXPHOS. We observed enlarged mtDNA nucleoids in "mito-bulbs" in H1650 cells after Drp1 knock down ([Figure S6I](#SD1){ref-type="supplementary-material"}), which is consistent with previous observations ([@R1]). Although Drp1 knockdown inhibited mitochondrial OXPHOS ([Figure S6J](#SD1){ref-type="supplementary-material"}), there was no decrease in mtDNA levels or mt-ND1 expression ([Figures S6K](#SD1){ref-type="supplementary-material"} and [S6L](#SD1){ref-type="supplementary-material"}). Importantly, Drp1 knockdown had no effect on fascin-mediated increase in Complex I proteins and fascin-mediated augmentation of mitochondrial OXPHOS ([Figures S6M](#SD1){ref-type="supplementary-material"} and [S6N](#SD1){ref-type="supplementary-material"}). Taken together, our data suggest that fascin regulates the mtDNA nucleoid homeostasis through mtF-actin-dependent and at least partly Drp1-independent mechanisms. The loss of mtDNA in fascin-depleted cells may result in transcriptional and/or translational downregulation of mtDNA-encoded proteins, which would inhibit the assembly of respiratory complexes and destabilize the nuclear-DNA-encoded respiratory subunits.

Fascin Promotes Metabolic Stress Resistance and Lung Cancer Metastasis by Remodeling mtF-Actin and Augmenting Mitochondrial OXPHOS {#S8}
----------------------------------------------------------------------------------------------------------------------------------

To determine the role of mtF-actin in fascin-mediated metabolic stress resistance, we determine the effects of INF2-CAAX knockdown on resistance to glucose limitation and phenformin-induced cell death. As shown in [Figures 7A](#F7){ref-type="fig"} and [7B](#F7){ref-type="fig"}, fascin promotes cell proliferation and survival under metabolic stresses induced by glucose limitation and phenformin treatment, which was abrogated after depletion of INF2-CAAX, suggesting that mtF-actin is required for fascin-mediated metabolic stress resistance. To investigate the role of mtF-actin in fascin-mediated metastasis, we injected luciferase-labeled H292 cells into nude mice by tail vein and monitored the H292 metastasis through bioluminescence imaging. Although ectopically expressed fascin had only a marginal effect on whole-body photon flux, it markedly increased bioluminescence signals in the head ([Figures S7A](#SD1){ref-type="supplementary-material"}--[S7C](#SD1){ref-type="supplementary-material"}), implicating increased brain metastasis in the fascin-overexpression group. *Ex vivo* brain imaging demonstrated that fascin overexpression enhanced H292 metastasis to the brain by 14-fold and remarkably increased the incidence of brain metastasis from 37.5% to 100% ([Figures 7C](#F7){ref-type="fig"} and [7D](#F7){ref-type="fig"}). The presence of brain metastases in the fascin-over-expression group was also confirmed by H&E staining of the brain sections ([Figure S7D](#SD1){ref-type="supplementary-material"}). The INF2-CAAX knockdown decreased whole-body photon flux by over 90% ([Figure S7A](#SD1){ref-type="supplementary-material"}) and abrogated the fascin-mediated increase in brain metastasis ([Figures 7C](#F7){ref-type="fig"} and [7D](#F7){ref-type="fig"}; [Figure S7A](#SD1){ref-type="supplementary-material"}), suggesting that mtF-actin is required for fascin to promote lung cancer brain metastasis.

To investigate the role of mitochondrial OXPHOS in fascin-mediated metastasis, we ectopically expressed NDI1, a single-subunit yeast NADH-ubiquinone oxidoreductase, in fascin KO LLC cells. Ectopic NDI1 allows mitochondria to bypass the defective Complex I to use NADH as an electron donor for mitochondrial electron transfer ([Figure S7E](#SD1){ref-type="supplementary-material"}) ([@R3]; [@R28]). NDI1 ectopic expression in fascin KO cells was able to rescue reserved-capacity OCRs and remarkably restore the resistance to glucose limitation ([Figures S7F](#SD1){ref-type="supplementary-material"} and [S7G](#SD1){ref-type="supplementary-material"}) and metabolic stress-induced cell death (induced by glucose limitation and phenformin) ([Figure 7E](#F7){ref-type="fig"}; [Figure S7H](#SD1){ref-type="supplementary-material"}) and to rescue anchorage-independent growth ([Figure 7F](#F7){ref-type="fig"}). Fascin KO also remarkably increased both mitochondrial and cytosolic reactive oxygen species (ROS), which could be mitigated by the ectopic expression of NDI1 ([Figure S7I](#SD1){ref-type="supplementary-material"}), suggesting that fascin might regulate redox balance in lung cancer cells through Complex I regulation. Indeed, supplementation of antioxidant N-acetyl-cysteine (NAC) and (2-(2,2,6,6-Tetramethylpiperidin-1-oxyl-4-ylamino)-2-oxoethyl)triphenylphosphonium chloride (mitoTEMPO) was able to restore the resistance to phenformin and glucose limitation in fascin KO lung cancer cells ([Figures S7J](#SD1){ref-type="supplementary-material"} and [S7K](#SD1){ref-type="supplementary-material"}). To determine the role of mitochondrial OXPHOS in fascin-mediated metastatic colonization, we injected control or fascin KO LLC cells with or without ectopic NDI1 into albino BL6 mice by their tail vein. Fascin depletion in LLC cells abrogated the lung colonization and remarkably prolonged the survival of albino BL6 mice; the ectopically expressed NDI1 in fascin KO LLC cells was able to at least partially restore lung colonization and remarkably shorten survival in mice ([Figures 7G](#F7){ref-type="fig"} and [7H](#F7){ref-type="fig"}), strongly supporting the notion that fascin controls lung cancer metastasis through augmenting mitochondrial OXPHOS.

DISCUSSION {#S9}
==========

Here, we report fascin and mtF-actin as regulators of mitochondrial OXPHOS and mtDNA homeostasis in lung cancer. The depletion of fascin destabilizes mtF-actin and interferes with mtDNA maintenance, which results in mtDNA loss. mtDNA encodes essential subunits of respiratory complexes I, III, IV, and V and two mitochondrial ribosomal RNAs. The loss of mtDNA in fascin-depleted lung cancer cells resulted in the inhibition of respiratory complex biogenesis and metabolic stress resistance. By promoting mitochondrial OXPHOS and metabolic stress resistance, fascin promotes metastatic expansion. Taken together, our data support that fascin plays a metabolic role in the metastatic colonization of NSCLC ([Figure S7L](#SD1){ref-type="supplementary-material"}).

The regulation of mitochondrial metabolism and mtDNA homeostasis by fascin and mtF-actin appears to be partly through mechanisms distinctly different from Drp1-mediated mitochondrial fission. A previous report suggested that β-actin and myosin II were integral components of mtDNA nucleoids ([@R33]). However, our data and that of others indicate that fascin and mtF-actin are at the cytosolic side of the mitochondrial outer membrane ([@R16]; [@R18]; [@R29]). Intriguingly, although cortactin and the Arp2/3 complex have also been reported to promote mtF-actin assembly, inhibition of these two proteins has no effect on the mitochondrial recruitment of fascin. One possibility is that cortactin and the Arp2/3 complex facilitate the polymerization of dendritic actin networks, which is not compatible with fascin-mediated bundling of parallel actin filaments. The inhibition of Arp2/3 or depletion of cortactin also had no effects on mitochondrial OXPHOS or the biogenesis of respiratory Complex I, suggesting that the regulation of mitochondrial metabolism is specific to INF2-CAAX-mediated, ER-originated mtF-actin. The ER network is responsible for important cellular stress responses ([@R47]; [@R48]). There is recent evidence that the ER-mitochondrial contacts are required for initiating mtDNA replication ([@R21]). It is possible that fascin and mtF-actin modulate the mtDNA homeostasis and augment mitochondrial metabolism through the ER-mitochondrial crosstalk.

Our data indicate that fascin is able to regulate mitochondrial metabolism and metastatic expansion in NSCLC by remodeling mtF-actin. Although the dysregulated actin cytoskeleton in cancer cells has been extensively studied in the context of metastatic dissemination, the post-dissemination role of the actin cytoskeleton in metastatic progression is unclear. Our findings in NSCLC models suggest that the rearrangement of the actin cytoskeleton in metastatic cancer cells is able to reprogram mitochondrial metabolism to promote the survival and metastatic expansion of disseminated cancer cells.

Fascin expression is absent in most adult epithelial cells (including lung epithelial cells) ([@R12]), suggesting that it is optional for the normal physiology and metabolism in non-transformed epithelia. Intriguingly, metastatic cancer cells dramatically increase fascin expression, possibility in response to the inflammatory and hypoxic tumor microenvironment ([@R40]; [@R42]; [@R56]). Our data indicate that fascin confers a survival advantage to cancer cells in the nutrient-deprived tumor environment by augmenting mitochondrial metabolism and metabolic stress resistance. On the other hand, lung cancer overexpressing fascin might also become addicted to fascin-mediated mitochondrial metabolism through non-oncogene addictions ([@R27]), which likely creates a therapeutic vulnerability that could be exploited to prevent metastatic recurrence in fascin-overexpressing lung cancer.

Taken together, our studies revealed an unexpected role of fascin in the metastatic colonization of NSCLC by augmenting mitochondrial OXPHOS. However, there are a few outstanding questions and limitations that remain to be addressed in the future. First, although our data demonstrate that fascin regulates mitochondrial metabolism in lung adenocarcinoma, it is still unclear whether such findings could be extrapolated to other cancer types. Second, the role of mitochondria in tumor initiation, metastasis, and progression appeared to be dependent on tumor histology and stage. For example, there was evidence in colorectal cancer, breast cancer, and melanoma that mild inhibition of mitochondrial OXPHOS promotes tumor initiation and metastasis ([@R32]; [@R51]). In a recent study, [@R34] surveyed the changes in mtDNA copy number across 15 different types of cancer (relative to paired normal tissue) and discovered that lung adenocarcinoma was the only cancer type with increased mtDNA copies in cancer tissues. The elevated mitochondrial OXPHOS in lung adenocarcinoma could be in part due to genetic disruption of the switch/sucrose non-fermentable (SWI/SNF) complex ([@R25]), which promotes lung cancer tumor growth and progression. Third, this study used a tail-vein injection model to study the mitochondrial role of fascin in metastatic colonization and expansion. Although the choice of this experimental approach is oriented toward investigating the post-dissemination role of fascin in lung cancer metastasis, it would not be able to address the mitochondrial role of fascin in tumor cell migration, invasion, and metastatic dissemination. Interestingly, there is evidence that mitochondrial dynamics could have critical roles in cell migration and invasion ([@R55]). Therefore, future investigation using orthotopic metastasis models and cell migration and invasion assays is warranted.

STAR★METHODS {#S10}
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LEAD CONTACT AND MATERIALS AVAILABILITY {#S11}
---------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Shengyu Yang (<sxy@psu.edu>). Plasmids generated in this study will be available upon request with Material Transfer Agreements.

EXPERIMENTAL MODEL AND SUBJECT DETAILS {#S12}
--------------------------------------

### Cell culture {#S13}

The lung cancer cell lines (H1650, H23, H292 and LLC) were obtained from the ATCC and Moffitt Cancer Center Lung Cancer Center of Excellence cell line repository and authenticated using Short Tandem Repeat profiling. All cell lines used were free of microbial (including mycoplasma) contamination. H1650, H23, H292 were cultured in RPMI medium supplemented with 10% fetal bovine serum and 1% Penicillin-Streptomycin. LLC was cultured in DMEM medium supplemented with 10% fetal bovine serum and 1% Penicillin-Streptomycin. All the cells were maintained at 37°C in a humidified 5% CO~2~ incubator.

### CRISPR/Cas9 knockout in lung cancer cells {#S14}

Fascin knock out was performed using pLenti CRISPR V2 vector (Addgene_52961) ([@R35]) encoding sgRNA targeting Fascin (human Fascin: sgRNA, GAAGAAGCAGATCTGGACGC; mouse Fascin: sgRNA, TCGCTACCTGGCCGCCGACA). To generate stable fascin knockout lung cancer cells, cells were infected with control or sgRNA encoding lentiviral vectors, selected with puromycin and pooled together after drug selection. The depletion of fascin in the cells were confirmed using western blotting.

### Inducible Cas9 knockout of fascin in LLC cells {#S15}

LLC cells were infected with pLenti CMVtight -Cas9 Hygro and pLenti CMV rtTA3 Blast (w756-1) (Addgene_26429) and selected with hygromycin and blasticidin. Single clones were induced with 1 μg/ml doxycycline for 3 days and stained with anti-Flag antibody to examine the expression levels of Tet-On Flag-Cas9. 15 clones with high Cas9 expression were combined, infected with pLentiGuide.Puro selected with puromycin. The cells were then treated with 1ug/ml doxycycline for 7 days, and the expression of Flag-Cas9 and deletion of fascin were examined by western blotting.

### Animal models {#S16}

All animal experiments were performed following the NIH guidelines and according to protocols approved by the Moffitt Cancer Center IACUC or the Penn State College of Medicine IACUC. 6-7 weeks old NCr nu/nu mice (male or female) and Albion BL6 mice (female) were purchased from Charles Rivers and used in this study. Mice are housed in a pathogen-free facility and kept in a temperature-controlled room set to a light and dark cycle of 12 hours each. For the treatment studies mice were randomly assigned to different treatment group.

### Human tissue samples {#S17}

A total of 113 sequential lung adenocarcinoma tumor tissues were collected from patients who had received radical surgery at Tianjin Medical University Cancer Institute and Hospital (TJMUCH). Retrospective clinicopathological data of these patients, including age, sex, tumor size, regional lymph node status, TNM stage, pathologic type and survival data, were also obtained. These formaldehydefixed paraffin-embedded tissues were constructed into tissue microarrays for further immunohistochemistry analysis. Another set of 82 pairs of lung adenocarcinoma tumor tissues and corresponding adjacent non-tumor tissues were collected and sectioned to analyze the differential expression levels of fascin. The usage of these specimens and the patient information were approved by the Ethics Committee of TJMUCH. All patients provided written consent for the use of their specimens and disease information for future investigations according to the ethics committee. The age, and sex of the subjects is provided in [Tables S1](#SD1){ref-type="supplementary-material"} and [S3](#SD1){ref-type="supplementary-material"}. Sample size information is indicated in the figure legends.

METHOD DETAILS {#S18}
--------------

### cDNA constructs {#S19}

To rescue Fascin knockdown or overexpress Fascin proteins, wild-type or mutant Fascin (S39E and 149-151A mutants) ([@R54]) cDNAs were subcloned into pLenti.CMV.blasticidin vector (Addgene_17486) ([@R5]) between BamH I and XhoI sites. The inducible Cas9 construct was generated by inserting hSpCas9 PCR product (using pX330-U6-Chimeric_BB-CBh-hSpCas9 as template) ([@R7]) into pENTR TOPO® vector. The pENTR-Cas9 and pLenti CMVtight -DEST (Addgene_26433) was then used for the construction of pLenti CMVtight -Cas9 Hygro through LR recombination. pLNCX2-mApple-Lifeact has been previously reported ([@R44]) and deposited to Addgene_89820.

### Drug treatment {#S20}

To induce mtF-actin accumulation and EGFP-fascin recruitment to mitochondria, cells were incubated with 5 μM FCCP in cell culture medium (37°C, 5% CO2 for 60 minutes) or cultured in cell culture medium containing 1mM Glc (37°C, 5% CO2, for overnight) before being used for immunofluorescence staining. To inhibit protein translaction, cells were treated with doxycycline (10μg/ml) or cyclo-heximide (50 μg/ml) in cell culture medium for various time as indicated before being lysed for western blotting. To inhibit Arp 2/3 complex, cells were treated with 50 μM CK-666 for 24h (for western blotting) or overnight (for fluorescence imaging).

### RNA interference {#S21}

The knockdowns of Fascin and INF2-CAAX were achieved using pSUPER.Retro.puro vector (Oligoengine) encoding shRNA targeting mouse/human Fascin ([@R42], [@R43]), human Cortactin, and human INF2-CAAX ([@R18]). To rescue Fascin knockdown or overexpress Fascin proteins, wild-type or mutant Fascin (S39E and 149-151A mutants) ([@R54]) cDNAs were subcloned into pLenti.CMV.blasticidin vector (Addgene_17486) ([@R5]). pLKO vector encoding shRNAs for DRP1 were purchased from Sigma (sh1 TRCN0000318424; sh2 TRCN0000318425). The retroviral and lentiviral particles were packaged in HEK293 cells using the PEI transfection method, and concentrated as previously described ([@R53]).

### Western blotting {#S22}

Cells were lysed in SDS-NP40 buffer (50 mM Tris, pH 8.0, 150 mM NaCl, 1% NP40,1% SDS, 1mM protease inhibitors cocktail) on ice for 1 min. Cells were scraped from the plate and sonicated briefly three times. Then lysates were heated at 95°C for 5 min and centrifuged at 20,000 × g at 4°C for 10 min. To prepare cell lysate for detection of protein phosphorylation, cells were lysed in Triton x-100 buffer (50 mM Tris, pH 7.4, 150 mM NaCl, 1% Triton x-100, 1 mM EDTA, 1mM phosphatase inhibitor cocktail (Thermo Scientific, Cat\#88667), 1 mM protease inhibitors cocktail (Roche, Cat\# 04693159001)) on ice for 15 min. The protein concentrations of the cell lysates were determined using BCA method (Thermo Scientific Pierce, Cat\# PI-23225). 50 μg Proteins were separated by SDS-PAGE and transferred onto PVDF membrane. The membranes were incubated in blocking buffer (5% (w/v) nonfat dry milk in Tris-buffered saline, 0.05% Tween 20 (TBS-T)) for 30 min at RT., and incubated with primary antibodies for 16 h at 4°C, followed by incubation with secondary antibodies for 60 min at RT.

### Immunofluorescence staining and microscopy {#S23}

Immunofluorescence staining were carried out as previously described ([@R44]) with modifications. 80,000 cells were seeded onto laminin coated coverslips in 12-well plates overnight. Cells were then fixed with 4% fresh paraformaldehyde in phosphate buffered saline (PBS) at room temperature (RT) for 20 min. Cells were then incubated with primary antibodies (Alexa Fluor® 555 Mouse anti-Cytochrome C or rabbit anti-TOM20 for mitochondrial staining, mouse anti-DNA antibody, clone AC-30-10 for mtDNA nucleoid staining) diluted in antibody dilution buffer (2% BSA 0.1% Triton X-100 in TBS) for 60 min at RT. When F-actin staining was needed, Alexa Fluor 488 phalloidin (0.4 unit/ml) was included in the primary antibody solutions. Cells were then incubated with secondary antibodies for 60 min at RT and then with DAPI at RT for 10 min. Extensive washing with TBS was performed between each step. After a final wash with TBS the coverslips were mounted with Fluoromount (Sigma).

For Fascin staining, cells were fixed with cold (−20°C) methanol and incubated at −20°C for 20 min. After fixation, cells were rehydrated with 2% BSA 0.1% Triton X-100 in TBS for at RT for 20 min and then incubated with anti-Fascin and anti-TOM20 antibodies at 4°C for overnight. For EGFP-Fascin imaging, H23 cells were infected with pLNCX2-EGFP-Fascin1 retrovirus and pLV-mitoDsRed (Addgene_44386) lentivirus. 48 hours after infection, cells were imaged using Leica DMI8 TCS SP8 confocal microscope.

For wide-field fluorescence microscopy, samples were examined with an automated upright microscope (Axiovert S100) through a 63 × /1.3 FLUAR Plan Apochromatic oil immersion objective. Images were captured using the charge-coupled device camera (Axiocam 503 mono) and ZEN 2.3 blue edition (Zeiss). For confocal microscopy, samples were viewed with an inverted microscope (DMI8; Leica), confocal scanner (TCS SP8; Leica), and a HC PL APO 63 × /1.4 CS2 oil immersion objective (Leica). 488 and 552 STED laser lines were applied to excite the samples, and a tunable acousto-optical beam splitter was used to minimize crosstalk between fluorochromes. Gain, offset, pinhole, and lookup table settings were identical for all samples. Images were captured with photomultiplier detectors and prepared with the Leica Application Suite X (Leica).

### Immunohistochemistry (IHC) {#S24}

IHC staining was used to determine Fascin and NDUFB8 expression levels in tumor tissues and non-tumor tissues. Briefly, paraffin-embedded sections of tissues were deparaffinised and then heated in a pressure pot for 3 minutes to retrieve the antigens. The slides sections were then incubated with primary antibodies (1:200) overnight at 4°C. Antibody binding was detected using a peroxidase--conjugated secondary antibody at 37°C for 30 minutes. A DAB Substrate Kit was used to perform the chromogenic reaction. The intensity of the staining was evaluated by two independent investigators blinded to the clinicopathological data of patients using the following criteria: 0, negative; 1, low; 2, medium; 3, high. The extent of staining was scored as 0, 0% stained; 1, 1% to 25% stained; 2, 26% to 50% stained; 3, 51% to 100% stained. Five random fields (20 × magnification) were evaluated under a light microscope. The final scores were calculated by multiplying the scores of the intensity with those of the extent and dividing the samples into four grades: 0, negative (−); 1 to 2, low staining (+); 3 to 5, medium staining (++); 6 to 9, high staining (+++).

### Mitochondrial isolation {#S25}

All the mitochondrial isolation steps were carried out at 4°C or on ice. 5×10^6^ cells were harvested by scraping, washed once with mitochondrial isolation buffer (MIB, 200 mM sucrose, 10 mM Tris, 1 mM EGTA, using HEPES-KOH to adjust to pH 7.5. Fresh 1X protease inhibitor cocktail was added prior to for mitochondrial isolation). Cells were resuspended in 1ml MIB, and passed through 27G needle 30-35 times to break the cells. The cell lysate were then centrifuged at 500 × g for 10min. The supernatant was transferred to a new tube and then centrifuged at 7,000 × g for 10min. The mitochondria in the pellet were washed once with MIB and centrifuged at 10,000 × g for another 10min. The pellet was then resuspended in 300 μl MIB and the amount of mitochondrial protein was determined using BCA method.

### Blue native electrophoresis and immunoblot {#S26}

Blue native (BN) electrophoresis was performed at 4°C using NativePAGETM precast gel (Thermo Scientific, Cat\# BN1001BOX) as previously described ([@R15]) with modifications. The BN sample buffer (BNSB, 5 μl native sample buffer, 8 μl digitonin, 7 μl sterilized water, for 50 μg mitochondria protein) were prepared using the NativePAGE Sample Prep Kit (Thermo Scientific, Cat\#BN2008). The BNSB was added to 50 μg of mitochondria pellet and mixed gently to avoid bubble formation. The mixture was incubated on ice for 30 min and then centrifuged at 20,000 × g at 4°C for 10 min. 20 μl supernatant was mixed with 2 μl Coomassie Brilliant Blue G-250 from the kit and loaded to the NativePAGETM gel (3%--12% Bis-Tris gel). The anode buffer (1x NativePAGETM running buffer) and cathode buffer A (anode buffer + 0.2g/L Coomassie Brilliant Blue G-250) were prepared from 20x NativePAGETM running buffer (Thermo Scientific, BN2001). After electrophoresis at 150 V, 4°C for 45 min, the cathode buffer A was replaced with cathode buffer B (cathode buffer A mixed with anode buffer at a ratio of 1:10) and continued at 250 V, 4° C for 90 min. The gel was then washed with transfer buffer (TB, 1 × NuPAGETM transfer buffer, Thermo Scientific, Cat\# NP00061, plus 10% methanol) for 3 times and then incubated with TB for 20 min at RT with shaking. The proteins on the gel were transferred to PVDF membrane using conventional western blotting transfer device (300 mA, 120 min, on ice). After the transfer was complete, the PVDF membrane was fixed with 10% acetic acid immediately for 10 min on a shaker. The membrane was then washed with deionized water (DDW) for 5 times (3 min each) and air-dried completely. The air-dried membrane was then washed with methanol for 5 times (3 min each), and then with DDW for 5 times (3 min each) and then subjected to western blotting using anti-OXPHOS antibody cocktail (Thermo Scientific, Cat\# 45-7999) plus anti-mtCO1 antibody (Fisher Scientific, Cat\# 43-9800), or antibodies for respective respiration complexes.

### Mitochondrial stress test {#S27}

Oxygen consumption rate (OCR) was determined with a Seahorse XF96 Extracellular Flux Analyzer (Agilent Seahorse Bioscience) following protocols recommended by the manufacturer. Cells were seeded on XF96 microplates (10,000 cells/well). Cells were maintained in a non-buffered assay medium (Agilent) in a non-CO2 incubator for 30 min before the assay. The XF Cell Mito Stress Test Kit (Agilent), was used for the assay. The baseline recordings were followed by sequential injection of 1 μM oligomycin, 1 μM FCCP, and 1 μM rotenone/ 20 μM antimycin A.

### NAD+ and NADH quantification {#S28}

The levels of NAD+ and NADH were determined using the NAD+ /NADH assay kit from Biovision (Cat\# k337-100). Approximately 200,000 cells were harvested and extract by 2x freeze/ thaw cycles in 400 μl Extraction Buffer. The extraction were centrifuged at 20,000 × g at 4°C for 5 min, and the supernatant was used to determine total NAD (NADt, NADH and NAD) and NADH according to the manufacturer's instruction.

### Soft agar assay {#S29}

Each 12-well plate was coated with 1 mL of bottom agar (prepared with RPMI/DMEM medium supplemented with 10% FBS and 0.75% low melting agar (Fisher Scientific, Cat\# BP165-25) and allowed to solidify. 3,000 cells were suspended in 1 mL top agar (RPMI/DMEM containing 10% FBS and 0.375% low melting agar) and seeded to each well. 1ml RPMI/DMEM complete medium were added to the well after the top agar solidified. The medium were replaced every three days. After 14-21 days, the colonies were stained with iodonitrotetrazolium chloride (Biosynth, Cat\# I-7630) overnight to visualize colony formation, and the number of colonies per well were quantified using ImageJ software.

### Cell proliferation assay {#S30}

Cells were seeded at 80,000/ well in a 6-well plate in triplicate in RPMI complete medium containing 10 mM or 1 mM glucose. The cell culture media were changed every day. Cells were fixed with 10% formalin for 20min and stained with 100 μl crystal violet solution (Eng Scientific, Cat\# INC NO. 6100) for 20 min with shaking. After washing, the crystal violet staining was solubilized with 1 mL 10% acetic acid and absorbance at OD 590 nm was measured.

### Cell phenformin sensitivity assay {#S31}

60,000 cells were seeded to 12 wells plate in RPMI medium containing 1 mM glucose and phenformin before being subjected to Propidium iodide (PI) staining to evaluate cell death. The phenformin treatment concentrations and times varied depending on cell lines and experimental conditions: H292 cells were treated with 40 μM phenformin for 48 h; LLC cells were treated with 20 μM phenformin for 24 h; H1650 and H23 cells were treated with 40 μM (for fascin depletion experiments), 100 μM (for H1650 fascin overexpression experiment) or 200 μM (for H23 fascin overexpression experiment) phenformin for 48 h.

### RNA isolation and qPCR {#S32}

1 × 10^6^ cells were washed with ice-cold PBS and total RNA was extracted using RNeasy Kit (QIAGEN Cat\# 74106). 1 μg RNA was used for the reverse transcription. cDNAwas diluted 1:10 then used for qPCR with ABI qPCR master mix (Thermo, Cat\# 4367659).

### Quantitation of cytosolic mtDNA {#S33}

The cytosolic mtDNA was quantified as previously described ([@R50]). 2 × 10^6^ cells were each divided into two equal aliquots, and one aliquot was used for total DNA extraction using DNeasy Kit (QIAGEN, Cat\# 69504). The second aliquots were resuspended in 500 μl buffer (150 mM NaCl, 50 mM HEPES, and 25 μl /ml digitonin (EMD), pH 7.5) and incubated on ice for 10 min to permeabilize the plasma membrane. The cell lysate were then centrifuged at 1000 × g, 5 min 3 times at 4°C. The supernatant was transferred to a new tube and centrifuge at 20000 × g for 10 min at 4°C. The cytosolic DNA in the supernatant was extracted using DNeasy Kit. Quantitative PCR was performed using DNA extracted from both whole-cell extracts and cytosolic fractions using nuclear DNA primers and mtDNA primers in [Table S3](#SD1){ref-type="supplementary-material"}.

### Lewis Lung Cancer (LLC) cell lung extravasation pilot experiment {#S34}

5 × 10^5^ mApple-Lifeact labeled LLC cells were suspended in 300 μl DMEM base medium and injected via tail vein into 7 week-old BL6 female mice. 2, 24 h, or 48 h after LLC cell injection, mice were tail-vein injected with 100 μl DyLight 488 Lycopersicon Esculentum Lectin (1mg/ml) (Vector Laboratories, Cat\#DL-1174) to label vascular endothelial cell marker. The mice are euthanized and the lungs were extracted for extra vital imaging using FV1000 MPE Multiphoton Laser Scanning Microscope (Olympus) and 60 × /0.9 LUM Plan FI/IR water immersion objective was used for imaging. Multi-line Argon 488 nm and Green HeNe 543 nm STED laser lines were applied to excite the samples, and a tunable acousto-optical beam splitter was used to minimize crosstalk between fluorochromes. Images were captured with photomultiplier detectors and prepared with FV10-ASW (Olympus).

Metastatic colonization

For H292 lung colonization experiments, nude mice were randomly assigned to two groups (8 mice each, female). 5 × 10^6^ luciferase labeled H292 cells were resuspended in 300 μl DMEM medium (serum free) and inoculated into 7 week-old female nude mice via tailvein. Noninvasive bioluminescent imaging by injecting specimen intra-peritoneal (i.p.) with 10 minutes prior to imaging with 150mg/kg of D-luciferin in DPBS, and analysis were performed as described previously with Xenogen IVIS 200 (8).

For LLC metastatic expansion experiment, 5 × 10^5^ luciferase labeled LLC cells stabling expressing Tet-On Cas9 and Fascin sgRNA were resuspended in in 300 μl DMEM medium (serum free) and tail-vein injected into 7 week-old Albino BL6 female mice. The mice were randomly assigned to two groups (10 mice each). One group was provided with doxycycline chow (BioServ, Cat\# S3888) 48 h after tail vein injection; the other group was continued with regular chow. Bioluminescence imaging was performed as indicated to monitor metastatic expansion of disseminated LLC cells. For pharmacological inhibition of Fascin, mice were randomly assigned to two groups (10 mice each, female).48 hours after tail-vein injection. Mice were administered daily with 100mg / kg G2 (Enamine, Cat\# EN300-246105) via i.p. or with vehicle control.

For H292 brain metastasis experiment, nude mice were randomly assigned to four groups (8 mice each, male), 5 × 10^6^ luciferase labeled H292 cells with or without Fascin overexpression or INF2-CAAX knockdown were injected via tail. To image brain metastasis, mice were i.p. injected with 150mg / kg D-luciferin and euthanized after 5 minutes. The brain was carefully extracted within 3 minutes and soaked 500 μl D-luciferin (15 mg / ml) solution at 37°C for 10 minutes before bioluminescence imaging.

For NDI1 rescue experiment, 5 × 10^5^ luciferase labeled LLC cells with or without Fascin knockout or NDI1 overexpression were tail-vein injected into Albino BL6 female mice. Bioluminescence imaging was performed as indicated to monitor metastatic colonization by disseminated LLC cells.

### Metabolomics and metabolic flux analysis {#S35}

Control or Fascin knockout H1650 cells were extracted with 80% methanol and metabolite extracts were analyzed through LC-MS/MS for relative metabolite changes using Selected Reaction Monitoring (SRM) method. About 280 polar metabolites encompassing different metabolic pathways including glycolysis, TCA cycle, nicotinamide metabolism, amino acid metabolism etc. were analyzed using Acquity UPLC and Xevo TQS (Waters) based platform ([@R39]). Peak areas were normalized with the respective protein concentrations and the resultant peak areas were subjected to metabolomic analyses by utilizing Metaboanalyst 2.0. Relative difference in metabolite levels were compared using Student's t test.

For metabolic flux analysis, 1×10^7^ H1650 cells were incubated with RPMI medium containing 10 mM \[U-13C\] Glucose for 6 hours. After washing with PBS once, the cells were extracted using 4 mL of cold (−20°C) 70% methanol and incubated in −80°C for 10 minutes. The labeled and unlabeled metabolites were analyzed through LC-MS using Thermos Exactive Plus Orbitrap Mass Spectrometer. Peak areas were normalized with the respective protein concentrations and the resultant peak areas were analyzed using MSDIAL 3.2.

### Proteomics {#S36}

To compare protein expression levels in control and Fascin KO cells, chemical labeling using tandem mass tags (TMT) was combined with liquid chromatography-tandem mass spectrometry discovery proteomics. Samples were prepared in biological duplicate. Protein lysates were made using aqueous denaturing buffer containing 20 mM HEPES and 8 M urea, prior to reduction of disulfides, alkylation of cysteines, and tryptic digestion (Worthington). The resulting peptides are extracted using C-18 Sep-Pak cartridges, dried, and resuspended in 100 mM aqueous triethylammonium bromide (TEAB) for TMT labeling. Each channel is analyzed with LC-MS/MS for quality control (i.e., tag incorporation and reporter ion verification). Then, samples are mixed using equal amounts of total protein and fractionated with basic pH reversed phase liquid chromatography; each peptide fraction is analyzed in duplicate with LC-MS/MS (RSLCnano and QExactive Plus, Thermo). Data are analyzed with MaxQuant ([@R8]), which identifies each peptide using sequence specific ions and quantifies relative expression level in each sample using the TMT Reporter ions. After iterative rank order normalization to correct for differences in loading, significant differences were determined as proteins that exceeded 2 times the standard deviation away from the mean log2 ratio between the two samples ([@R49]).

QUANTIFICATION AND STATISTICAL ANALYSIS {#S37}
---------------------------------------

All data are shown as mean values ± standard deviation (SD) unless indicated otherwise. Sample numbers of data obtained from animal experiments refer to the number of individual mice, as specified in the figure legends. Experiments on cultured cells were performed using at least 3 independent biological replicates. Log-rank tests were used for survival analysis. Categorical data were analyzed using Fisher's exact test or Chi-square test. Spearman's rank-order correlation was used to determine the correlation between immunohistochemistry staining intensities for different antigens. Comparison of two independent groups was performed with unpaired two-tailed Student's t test. No samples, data points, or animals were excluded from the analysis. Statistical analysis were performed using GraphPad Prism 7 or SPSS software.

DATA AND CODE AVAILABILITY {#S38}
--------------------------

The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository with the dataset identifier PXD014753 and 10.6019/PXD014753. Metabolomics data are available upon request.
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![Fascin Is Required for the Metastatic Expansion of NSCLC\
(A) Representative IHC staining showing fascin expression in normal lung and lung adenocarcinoma patient specimens.\
(B) Expression levels of fascin in 82 pairs of lung adenocarcinoma specimens (tumor) and paired para-tumor lung tissues. p value was determined by two-tailed Wilcoxon signed-rank tests.\
(C) The overall survival rate of lung adenocarcinoma patients with low or high fascin expression levels.\
(D and E) The effect of fascin knockout on the lung colonization of tail-vein-injected H292 cells (5 × 10^6^). Representative image of bioluminescence imaging (D) and quantitation of photon flux (n = 8, male nude mice) (E) are shown.\
(F) Schematics showing inducible fascin KO in extravasated LLC cells with doxycycline chow.\
(G and H) Representative bioluminescence imaging (BLI) (day 25) (G) and quantitation (H) (n = 10, female albino BL6 mice), showing that doxycycline (doxy)-induced fascin KO in extravasated LLC cells (2 days post-inoculation) inhibited metastatic expansion.\
(I and J) Representative BLI (day 20) (I) and quantitation (J) (n = 10, female albino BL6 mice), showing that fascin inhibitor G2 inhibited metastatic expansion by extravasated LLC cells.\
(K) The effects of fascin knockout (KO) or overexpression (OE) on H1650 cell proliferation under different concentrations of glucose in the medium.\
(L) Effects of fascin KO or OE on soft agar colony formation in NSCLC cells.\
(M) The effects of fascin KO on H1650 cell death when treated with different concentrations of phenformin.\
(N) The effects of fascin KO or OE on the sensitivity of NSCLC cell to phenformin-induced cell death.\
Data in (C) were analyzed using two-tailed log-rank test; data in (H) and (J)--(N) were analyzed using two-tailed, two-sample unpaired Student's t test. Data in (K)--(N) are representative results from at least three independent experiments (n = 3 biological replicates per group for each experiment).](nihms-1539603-f0001){#F1}

![Fascin Is Required for Mitochondrial OXPHOS in NSCLC Cells\
(A) The most differentially regulated metabolic pathways in fascin KO H1650 cells.\
(B) The effect of fascin depletion on NAD+ and NADH levels in H1650 cells. n = 5 independent samples per group.\
(C) Summary of ^13^C incorporation into TCA cycle metabolites in fascin KO H1650 cells after 6 h of labeling with \[U-^13^C\] glucose. Blue and red arrows indicate increases and decreases, respectively, in ^13^C incorporation into the indicated metabolite.\
(D) The levels of ^13^C incorporation into TCA cycle metabolites in control and fascin KO H1650 cells, as determined by LC-MS analysis. M+x represents the number of ^13^C-labeled carbon in each metabolite, presented in arbitrary peak intensity units. n = 5 biological replicates per group.\
(E) The effects of fascin KO or OE on mitochondrial oxygen consumption rates (OCR), as determined by mito-stress test. n = 3 biological replicates per group.\
(F and G) Quantitation of the effects of fascin KO (F) or OE (G) on basal, ATP-linked, and maximum capacity OCR in different NSCLC cell lines.\
Data in (B), (D), (F), and (G) were analyzed by two-tailed, two-sample unpaired Student's t test. Representative results from at least three (B and E--G) or two (C and D) independent experiments are shown.](nihms-1539603-f0002){#F2}

![Fascin Controls Mitochondrial OXPHOS by Remodeling mtF-Actin\
(A--D) The ectopic expression of wild-type fascin, but not the bundling defective mutants (S39E and 149-151A), in fascin knockdown H1650 cells was able to rescue mitochondrial OCR (A and B) and NAD+ and NADH levels (C and D). n = 3 biological replicates per group.\
(E and F) Representative images (E) and quantitation (F) showing constitutive F-actin recruitment to mitochondria in LLC cells.\
(G) Quantitation of mitochondrial F-actin in H23 cells under metabolic stress induced by glucose limitation (1 mM glucose \[Glc\]) or FCCP. n = 30--32 independent l-cell images per group.\
(H) Representative images showing the recruitment of EGFP-fascin to mitochondria under glucose limitation and the effects of INF2-CAAX knockdown on fascin recruitment under glucose-limited conditions.\
(I) Quantitation of the proportion of control or INF2-CAAX knockdown H23 cells with mitochondrial EGFP-fascin recruitment when subjected to glucose limitation or FCCP treatment. n = 30--32 independent confocal cell images per group.\
(J) Mito-stress test showing the effects INF2-CAAX knockdown on fascin-mediated augmentation of mitochondrial OXPHOS in H23 cells. n = 3 biological replicates per group.\
(K) Quantitation of the effects of INF2-CAAX knockdown on fascin-mediated augmentation of maximum capacity OCR in three NSCLC cell lines.\
Two-tailed, two-sample unpaired Student's t test (for B--D and K or Fisher's exact test (for F, G, and I) were used for analyses. Representative results from at least three independent experiments are shown.](nihms-1539603-f0003){#F3}

![Fascin and mtF-Actin Regulate the Biogenesis of Respiratory Complexes in NSCLC\
(A) Waterfall plot showing fold changes of 12 mitochondrial proteins differentially regulated in fascin KO H1650 cells. Fold changes (log~2~) are presented as mean ± SEM of results from two independent samples.\
(B and C) Western blotting showing the decrease in respiration Complex I subunits in fascin KO H1650 (B) and H23 (C) cells.\
(D and E) Western blotting showing the increase in the levels of Complex I subunits in H23 cells overexpressing wild-type fascin (D) but not the S39E and 149-151A mutants (E).\
(F) shRNA knockdown of INF2-CAAX abrogated fascin-mediated increase in mt-ND1 and NDUFB8 in H1650 cells.\
(G and H) The effect of fascin (G) and INF2-CAAX (H) depletion on the levels of respiratory super complexes in H1650 cells, as determined by BN-PAGE and western blotting using anti-OXPHOS antibody cocktails (recognized all 5 complexes) and antibodies specific for each respiratory complex (Cx I--V). S. C. indicates respirasomes consisting of Complex I, III, and IV.\
Representative results from at least three independent experiments are shown.](nihms-1539603-f0004){#F4}

![The Correlation between Fascin and NDUFB8 in Lung Cancer Patients\
(A) Representative immunohistochemistry staining images showing expression levels of NDUFB8 in lung adenocarcinoma patients.\
(B) The survival of lung adenocarcinoma patient with low (−,+) or high (++,+++) NDUFB8 expression. p value and hazard ratio (HR) was determined by two-railed log-rank test.\
(C) Fascin and NDUFB8 staining in consecutive sections from lung adenocarcinoma tissue microarray showing the correlation between fascin staining and NDUFB8 staining.\
(D) Correlation between fascin and NDUFB8 staining intensities in lung adenocarcinoma tissue microarray.\
Correlation coefficient and p value were calculated by Spearman correlation test.](nihms-1539603-f0005){#F5}

![Fascin and mtF-Actin Are Required for mtDNA Maintenance in NSCLC\
(A and B) H23 cells were treated with the eukaryotic ribosome inhibitor cycloheximide (CHX) (A) or mitochondrial ribosome inhibitor doxycline for the indicated time (B), and the protein levels of NDUFB8 and mt-ND1were determined by western blotting.\
(C) Fascin KO decreased the mRNA levels of mtDNA-encoded respiration complex subunits (Complex I: mt-ND1, mt-ND2; Complex III: mt-CO1; Complex IV: CytB; and Complex V: ATPase 6), mitochondrial ribosome 16S rRNA, without affecting the levels of nuclear-encoded NDUFA4, NDUFB8, and NDUFS1 in H23 cells. n = 3 biological replicates per group.\
(D) Representative images showing mtDNA nucleoid (anti-DNA, red) and mitochondrial staining (Tom20, green) in control and fascin KO H1650 cells. Arrows indicate mtDNA nucleoid aggregates.\
(E) The levels of cytosolic mtDNA in control and fascin KO NSCLC cells, as determined by qPCR. n = 3 biological replicates per group.\
(F) Representative images showing the effects of ectopically expressed wild-type fascin or bundling-defective mutants (S39E and 149-151A) on mtDNA aggregation in fascin-depleted H1650 cells. Arrows indicate mtDNA nucleoid aggregates.\
(G) Quantitation of the percentage of cells with mtDNA nucleoid aggregate in (F).\
(H and I) qPCR quantitation of the levels of mtDNA (H) or mtDNA-encoded RNA transcripts (I) in control, fascin knockdown, or knockdown-rescue H1650 cells.\
Data in (C), (E), and (G)--(I) were analyzed by two-tailed, two-sample unpaired Student's t test. NS, statistically not significant. Representative results from at least three independent experiments are shown.](nihms-1539603-f0006){#F6}

![Fascin Promotes Metabolic Stress Resistance and Lung Cancer Metastasis by Remodeling mtF-Actin and Augmenting Mitochondrial OXPHOS\
(A and B) The effects of fascin OE and INF2-CAAX knockdown on the resistance of H1650 cells to glucose limitation (1mM glucose) (A) and phenformin (B). n = 3 independent samples per group.\
(C and D) *Ex vivo* bioluminescence imaging (C) and quantitation of photon flux (D) showing the effects of fascin OE and INF2-CAAX knockdown on H292 brain metastasis in nude mice. n = 7 or 8 mice, as indicated, per group.\
(E and F) The effects of fascin KO and ectopic NDI1 expression on cell proliferation under glucose-limited conditions (1mM glucose) (E) and soft-agar colony formation (F) in LLC cells. n = 3 biological replicates per group.\
(G and H) Representative H&E staining (G) and survival analysis (H) showing the effects of fascin KO and ectopic NDI1 expression on lung metastasis by tail-veininjected LLC cells. n = 8, two-tailed log-rank test.\
Representative results from at least three independent experiments are shown in (A), (B), (E), and (F). Data were analyzed by two-tailed, two-sample unpaired Student's t test.](nihms-1539603-f0007){#F7}

###### 

KEY RESOURCES TABLE

  REAGENT or RESOURCE                                                                                                                      SOURCE                                                     IDENTIFIER
  ---------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------- ------------------------------------------------------------
  Antibodies                                                                                                                                                                                          
  Fascin 1 Antibody (55K-2)                                                                                                                Santa Cruz                                                 Cat\# SC-21743, RRID:AB_627580
  Tom20 Antibody (FL-145)                                                                                                                  Santa Cruz                                                 SC-11415, RRID:AB_2207533
  DRP1 Antibody (C-5)                                                                                                                      Santa Cruz                                                 SC-271583, RRID:AB_10659110
  Anti-Rabbit, HRP                                                                                                                         Cell Signaling                                             7074s, RRID:AB_2099233
  Anti-Mouse, HRP                                                                                                                          Cell Signaling                                             7076s, RRID:AB_330924
  INF2 antibody                                                                                                                            Millipore                                                  ABT61, RRID:AB_11203139
  Monoclonal Anti-GAPDH antibody                                                                                                           Sigma                                                      G8795, RRID:AB_1078991
  NDUFB8 antibody (20E9DH10C12)                                                                                                            Thermo Scientific                                          459210, RRID:AB_2532232
  NDUFA4 antibody                                                                                                                          Thermo Scientific                                          PA5-51021, RRID:AB_2636469
  MT-ND1 antibody                                                                                                                          Novus                                                      NBP100939, RRID:AB_1503736
  NDUFB10 antibody                                                                                                                         Thermo Scientific                                          PA5-51179, RRID:AB_2636627
  OXPHOS Complex Monoclonal antibody (Cocktail)                                                                                            Thermo Scientific                                          45-7999, RRID:AB_2533834
  Complex I NDUFA9 20C11B11B11                                                                                                             Thermo Scientific                                          459100, RRID:AB_2532223
  Complex II SDHA antibody (2E3GC12FB2AE2)                                                                                                 Thermo Scientific                                          459200, RRID:AB_2532231
  Complex III UQCRC2 antibody \[13G12AF12BB11\]                                                                                            Abcam                                                      ab14745, RRID:AB_2213640
  Complex IV MTCO1 antibody \[1D6E1A8\]                                                                                                    Abcam                                                      ab14705, RRID:AB_2084810
  Complex V ATP5A1 antibody (15H4C4)                                                                                                       Thermo Scientific                                          43-9800, RRID:AB_2533548
  Anti-DNA antibody, clone AC-30-10                                                                                                        Millipore                                                  CBL186, RRID:AB_93367
  Anti-cytochrome *c* antibody                                                                                                             Cell Signaling                                             4272, RRID:AB_2090454
  Alexa 488 goat anti-mouse                                                                                                                Thermo Scientific                                          A11001, RRID:AB_2534069
  Alexa 594 goat anti-mouse                                                                                                                Thermo Scientific                                          A11032, RRID:AB_141672
  Alexa 488 goat anti-rabbit                                                                                                               Thermo Scientific                                          A11008, RRID:AB_143165
  Alexa 594 goat anti-rabbit                                                                                                               Thermo Scientific                                          A11012, RRID:AB_2534079
  Alexa Fluor® 555 Mouse anti-Cytochrome *c* Clone 6H2.B4 (RUO) BD                                                                         BD Biosciences                                             558700, RRID:AB_1645293
  ANTI-FLAG® M2 antibody                                                                                                                   Sigma                                                      F3165, RRID:AB_259529
  PLS3 (Fimbrin) antibody                                                                                                                  Thermo Scientific                                          PA5-27883, RRID:AB_2545359)
  Cortactin antibody                                                                                                                       Millipore                                                  05-180, RRID:AB_309647
  Bacterial and Virus Strains                                                                                                                                                                         
  Stable Competent *E. coli* (High Efficiency)                                                                                             NEB                                                        C3040I
  pLenti-CMV-blasticidin                                                                                                                   [@R5]                                                      Addgene_17486
  pLV-mitoDsRed                                                                                                                            [@R17]                                                     Addgene_44386
  pLX304-PLS3 (Fimbrin)                                                                                                                    Harvard Plasmids                                           NP_001129497.1
  pLenti-PGK V5-LUC Neo (w623-2)                                                                                                           [@R5]                                                      Addgene_21471
  pLenti-CRISPR V2 vector                                                                                                                  [@R35]                                                     Addgene_52961
  pLKO-DNM1L (DRP1) shRNA1                                                                                                                 Sigma                                                      TRCN0000318424
  pLKO-DNM1L (DRP1) shRNA2                                                                                                                 Sigma                                                      TRCN0000318425
  pLenti-Guide-Puro                                                                                                                        [@R35]                                                     Addgene_52963
  pLenti CMV rtTA3 Blast (w756-1)                                                                                                          Eric Campeau                                               Addgene_26429
  pLenti CMVtight Hygro DEST (w769-1)                                                                                                      Eric Campeau                                               Addgene_26433
  pLNCX2-mApple-Lifeact                                                                                                                    [@R44]                                                     Addgene_89820
  pX330-U6-Chimeric_BB-CBh-hSpCas9                                                                                                         [@R7]                                                      Addgene_42230
  Biological Samples                                                                                                                                                                                  
  A total of 113 sequential lung adenocarcinoma tumor tissues were collected from patients                                                 Tianjin Medical University Cancer Institute and Hospital   N/A
  Another set of 82 pairs of lung adenocarcinoma tumor tissues and corresponding adjacent non-tumor tissues were collected from patients   Tianjin Medical University Cancer Institute and Hospital   N/A
  Chemicals, Peptides, and Recombinant Proteins                                                                                                                                                       
  Fetal Bovine Serum                                                                                                                       Atlanta Biological                                         S11150
  Penicillin/Streptomycin                                                                                                                  GIBCO                                                      15140163
  DMEM Medium                                                                                                                              HyClone                                                    SH30243.FS
  DMEM Medium, no glucose                                                                                                                  GIBCO                                                      11966025
  RPMI 1640 Medium                                                                                                                         HyClone                                                    SH30027.FS
  RPMI 1640 Medium, no glucose                                                                                                             GIBCO                                                      11879020
  FCCP                                                                                                                                     Abcam                                                      NC0474145
  Blebbistatin                                                                                                                             Sigma                                                      B0560
  Doxycycline                                                                                                                              Fisher Scientific                                          BP2653-1
  Cycloheximide (CHX)                                                                                                                      Sigma                                                      C7698
  Protease inhibitors cocktail                                                                                                             Roche                                                      04693159001
  Phosphatase inhibitor cocktail                                                                                                           Thermo Scientific                                          88667
  Fluoromount                                                                                                                              Sigma                                                      F4680
  DAPI (4',6-Diamidino-2-Phenylindole, Dihydrochloride)                                                                                    Thermo Scientific                                          D1306
  NativePAGETM precast gel                                                                                                                 Thermo Scientific                                          BN1001BOX
  NativePAGETM running buffer                                                                                                              Thermo Scientific                                          BN2001
  NuPAGETM transfer buffer                                                                                                                 Thermo Scientific                                          NP00061
  Brilliant Blue G                                                                                                                         Sigma                                                      B0770
  PVDF Transfer Membranes                                                                                                                  Millipore                                                  IPVH00010
  Methanol                                                                                                                                 Fisher Scientific                                          BP11054
  Low melting agar                                                                                                                         Fisher Scientific                                          BP165-25
  iodonitrotetrazolium chloride                                                                                                            Biosynth,                                                  I-7630
  Formalin 10%                                                                                                                             Fisher Scientific                                          SF100-4
  Paraformaldehyde                                                                                                                         Sigma                                                      158127
  Crystal violet solution                                                                                                                  Eng Scientific                                             INC NO. 6100
  Propidium iodide                                                                                                                         Sigma                                                      P4170
  Digitonin                                                                                                                                EMD                                                        
  DyLight 488 Lycopersicon Esculentum Lectin                                                                                               Vector Laboratories                                        DL-1174
  D-Luciferin Sodium Salt                                                                                                                  Regis Tech                                                 103404-75-7
  Doxycycline chow                                                                                                                         BioServ                                                    S3888
  G2 inhibitor                                                                                                                             Enamine                                                    EN300-246105
  D-Glucose-^13^C6                                                                                                                         Sigma                                                      389374
  CK-666                                                                                                                                   Sigma                                                      SML0006
  Phenformin hydrochloride                                                                                                                 Sigma                                                      P7045
  DNase I, RNase-free                                                                                                                      Thermo Scientific                                          EN0525
  Critical Commercial Assays                                                                                                                                                                          
  NAD+ /NADH Assay Kit                                                                                                                     Biovision                                                  k337-100
  DAB Peroxidase (HRP) Substrate Kit                                                                                                       Vector                                                     SK-4100
  NativePAGE Sample Prep Kit                                                                                                               Thermo Scientific                                          BN2008
  XF Cell Mito Stress Test Kit                                                                                                             Agilent                                                    103015-100
  RNeasy Kit                                                                                                                               QIAGEN                                                     74106
  DNeasy Kit                                                                                                                               QIAGEN                                                     69504
  ABI qPCR master mix                                                                                                                      Thermo Scientific                                          4367659
  Experimental Models: Cell Lines                                                                                                                                                                     
  H1650                                                                                                                                    ATCC                                                       CRL-5883
  H23 (microbial (including mycoplasma) verified free)                                                                                     Moffitt Cancer Center                                      N/A
  H292                                                                                                                                     ATCC                                                       CRL-1848
  LLC (microbial (including mycoplasma) verified free)                                                                                     Moffitt Cancer Center                                      N/A
  HEK293                                                                                                                                   ATCC                                                       CRL-1573
  Experimental Models: Organisms/Strains                                                                                                                                                              
  B6 Albino Mouse                                                                                                                          Charles River                                              Strain Code 493
  NU/NU Nude Mouse                                                                                                                         Charles River                                              Strain Code 088
  Oligonucleotides                                                                                                                                                                                    
  See [Table S4](#SD1){ref-type="supplementary-material"}                                                                                                                                             
  Recombinant DNA                                                                                                                                                                                     
  pLNCX2-EGFP-Fascin1 human                                                                                                                This paper                                                 N/A
  pSUPER.Retro.puro-Fascin1 (human/mouse): GGTGGGCAAAGATGAGCTC                                                                             [@R42]                                                     N/A
  pSUPER.Retro.puro-shINF2-CAAX: ACAAAGAAACTGTGTGTGA                                                                                       This paper                                                 N/A
  pSUPER.Retro.puro-Cortactin sh1: GGTTTCGGCGGCAAATACG                                                                                     This paper                                                 N/A
  pSUPER.Retro.puro-Cortactin sh2: CGAATATCAGTCGAAACTT                                                                                     This paper                                                 N/A
  pLenti-CRISPR V2-puro-Fascin1 human: GAAGAAGCAGATCTGGACGC                                                                                This paper                                                 N/A
  pLenti-CRISPR V2-puro-Fascin1 mouse: TCGCTACCTGGCCGCCGACA                                                                                This paper                                                 N/A
  pLenti-CMV-Fascin1 wt human                                                                                                              This paper                                                 N/A
  pLenti-CMV-Fascin1 s39e human                                                                                                            This paper                                                 N/A
  pLenti-CMV-Fascin1 149-151A human                                                                                                        This paper                                                 N/A
  pLenti CMVtight -Cas9 Hygro                                                                                                              This paper                                                 N/A
  Software and Algorithms                                                                                                                                                                             
  MS-DIAL                                                                                                                                  [@R46]                                                     <http://prime.psc.riken.jp/Metabolomics_Software/MS-DIAL/>
  MaxQuant                                                                                                                                 [@R8]                                                      <https://maxquant.org>
  Metaboanalyst 2.0                                                                                                                        [@R52]                                                     <https://www.metaboanalyst.ca>
  Prism                                                                                                                                    GraphPad                                                   Version 7

###### Highlights

-   Fascin is required for metabolic stress resistance in metastatic lung cancer

-   Fascin promotes mitochondrial OXPHOS through remodeling mtF-actin

-   Fascin augments the biogenesis of Complex I through mtDNA homeostasis

-   The mitochondrial role of fascin is required for it to promote brain metastasis
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